- Category: News
- Published on Friday, 18 March 2011 10:18
- Written by L. Tacita
- Hits: 456
Biosante has not yet released Libigel, but stock market analysts are starting to react favorably to the drug. So far, Biosante is one of the few pharmaceutical companies seeking FDA approval for a drug to treat HSDD in women.
The product, which has not yet been approved by the FDA would be the first drug on the US marked for treatment of the condition. Biosante has consistently stated that the drug is designed to treat the condition in post menopausal women.
Analyst Jason Butler believes the shares are currently undervalued, according to the Associated Press. Biosante hopes to have Libigel on the market next year to tap into the $2 billion dollar female Viagra market. Flibanserin, a drug which did not alter levels of testorone, was denied FDA approval earlier this year.